Kymera Therapeutics Inc

11 de set. de 2026, 19:52 UTC

Kymera Therapeutics Inc is lower today, pulling back from earlier gains amid speculation about Federal Reserve interest rate hikes and broader market trends.

10 de set. de 2026, 20:07 UTC

Wolfe Research upgraded Kymera Therapeutics to Outperform, setting a price target of $180. Shares are trading higher amid increased investor interest.

9 de set. de 2026, 20:07 UTC

Kymera Therapeutics Inc shares are lower Wednesday, reflecting broader market pressures amid rising crude oil prices and inflation concerns.

8 de set. de 2026, 20:07 UTC

Kymera Therapeutics shares are lower amid insider selling, including a recent sale by Brian Adams. The stock has seen a cumulative decline since Friday.

2 de set. de 2026, 19:46 UTC

Shares rise as JPMorgan raises price target to $140.00.

28 de ago. de 2026, 20:01 UTC

Kymera Therapeutics Inc shares are lower today, continuing a decline since Thursday. Trading volume is unusually high amid rising U.S. Treasury yields.

27 de ago. de 2026, 20:02 UTC

Kymera Therapeutics Inc shares are lower today, diverging from recent gains amid high trading volume and broader market resilience following a drop in jobless claims.

25 de ago. de 2026, 20:07 UTC

Kymera Therapeutics shares are higher today, supported by declining oil prices and lower Treasury yields, enhancing overall investor sentiment toward equities.

21 de ago. de 2026, 19:26 UTC

Kymera Therapeutics Inc shares are lower during Friday's session despite earlier gains. Analysts maintain a consensus "Moderate Buy" rating with a target of $125.65.

20 de ago. de 2026, 22:01 UTC

Kymera Therapeutics Inc. shares are higher in after-market trading, supported by a broader upward trend in biotechnology stocks. The price remains above its 20-day moving average.

19 de ago. de 2026, 20:02 UTC

Kymera Therapeutics is rising amid gains in the ARK Genomic Revolution ETF, which increased significantly. The stock is also experiencing high market volume today.

18 de ago. de 2026, 19:26 UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier decline. No specific news was identified to explain the movement.

17 de ago. de 2026, 19:54 UTC

Kymera Therapeutics Inc shares are trading higher today amid increased volume, maintaining a positive trend since Friday's close despite earlier intraday fluctuations.

14 de ago. de 2026, 20:06 UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier pullback amid a mixed market backdrop following a decline in U.S. retail sales.

12 de ago. de 2026, 20:01 UTC

Kymera Therapeutics Inc shares are trading higher amid increased activity and unusually high market volume, with no specific news identified to explain the movement.

6 de ago. de 2026, 19:56 UTC

Kymera Therapeutics Inc shares are lower today, trading near the lower end of their one-month range amid broader market dynamics and inflationary concerns.

5 de ago. de 2026, 20:02 UTC

Kymera Therapeutics reported a narrower net loss of $61.21 million for Q2 2026, driven by increased collaboration revenue and a price target raise from Stifel to $132.

4 de ago. de 2026, 20:04 UTC

Kymera Therapeutics Inc is rising in Tuesday's session, reflecting bullish sentiment in the biotechnology sector amid a broader market uptrend.

3 de ago. de 2026, 19:46 UTC

Kymera Therapeutics Inc shares are lower amid volatility, following Dimensional Fund Advisors LP's 5% stake reduction and broader market trends in biotechnology.

31 de jul. de 2026, 20:06 UTC

Kymera shares lower amid SPDR S&P Biotech ETF decline.

30 de jul. de 2026, 19:39 UTC

Kymera Therapeutics Inc shares are higher during Thursday's session, with no specific news identified to explain the price action amid broader market trends.

29 de jul. de 2026, 19:32 UTC

Kymera Therapeutics shares are higher as the Federal Reserve maintains rates at 3.50%–3.75%. Investors monitor inflation trends and their impact on future policy.

28 de jul. de 2026, 17:42 UTC

Shares lower despite Guggenheim's price target increase to $135.

27 de jul. de 2026, 21:03 UTC

Kymera Therapeutics shares are lower in after-market hours following the appointment of Terence Rooney, MD, as Chief Medical Officer, succeeding Jared Gollob, MD.

24 de jul. de 2026, 18:46 UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

21 de jul. de 2026, 19:16 UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

20 de jul. de 2026, 22:16 UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.